EP1315830A4 - Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen - Google Patents

Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen

Info

Publication number: EP1315830A4
Authority: EP; European Patent Office
Prior art keywords: disclosed; peptides; methods; targeting; novel
Prior art date: 2000-09-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP01970681A

Other languages

English (en)

French (fr)

Other versions

EP1315830A2 (de

Inventor

Wadih Arap

Renata Pasqualini

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Texas System

University of Texas at Austin

Original Assignee

University of Texas System

University of Texas at Austin

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-09-08

Filing date

2001-09-07

Publication date

2005-10-19

2001-09-07 Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System

2003-06-04 Publication of EP1315830A2 publication Critical patent/EP1315830A2/de

2005-10-19 Publication of EP1315830A4 publication Critical patent/EP1315830A4/de

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Oncology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Neurology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)

EP01970681A 2000-09-08 2001-09-07 Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen Withdrawn EP1315830A4 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US23126600P	2000-09-08	2000-09-08
US231266P		2000-09-08
US76510101A	2001-01-17	2001-01-17
US765101		2001-01-17
PCT/US2001/028044 WO2002020723A2 (en)	2000-09-08	2001-09-07	Compositions and methods for targeting peptides in humans in vivo

Publications (2)

Publication Number	Publication Date
EP1315830A2 EP1315830A2 (de)	2003-06-04
EP1315830A4 true EP1315830A4 (de)	2005-10-19

Family

ID=26924954

Family Applications (6)

Application Number	Title	Priority Date	Filing Date
EP01970681A Withdrawn EP1315830A4 (de)	2000-09-08	2001-09-07	Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
EP01968603A Expired - Lifetime EP1322755B1 (de)	2000-09-08	2001-09-07	Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01968683A Withdrawn EP1315840A4 (de)	2000-09-08	2001-09-07	Biopanning und schnelle analyse von selektiven interaktiven liganden
EP01970682A Withdrawn EP1315512A4 (de)	2000-09-08	2001-09-07	Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden
EP01970671A Withdrawn EP1315965A4 (de)	2000-09-08	2001-09-07	Verfahren und zusammensetzungen für "targeting" in vitro
EP08016646A Withdrawn EP2028187A1 (de)	2000-09-08	2001-09-07	Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
EP01968603A Expired - Lifetime EP1322755B1 (de)	2000-09-08	2001-09-07	Durch phagendisplay identifizierte zielpeptide des menschen und der maus
EP01968683A Withdrawn EP1315840A4 (de)	2000-09-08	2001-09-07	Biopanning und schnelle analyse von selektiven interaktiven liganden
EP01970682A Withdrawn EP1315512A4 (de)	2000-09-08	2001-09-07	Zielgerichtetes einbringen mit hilfe von adenoviren und adenovirale manipulationder immunsystemantwort unter verwendung von zielgerichteten peptiden
EP01970671A Withdrawn EP1315965A4 (de)	2000-09-08	2001-09-07	Verfahren und zusammensetzungen für "targeting" in vitro
EP08016646A Withdrawn EP2028187A1 (de)	2000-09-08	2001-09-07	Durch Phagenanzeigen identifizierte, auf Menschen und Mäuse abgezielte Peptide

Country Status (7)

Country	Link
EP (6)	EP1315830A4 (de)
JP (6)	JP2004530404A (de)
AT (1)	ATE478141T1 (de)
CA (5)	CA2421271A1 (de)
DE (1)	DE60142840D1 (de)
PT (1)	PT1322755E (de)
WO (4)	WO2002020822A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2313779T3 (es) *	1998-03-13	2009-03-01	The Burnham Institute	Moleculas que migran a diversos organos o tejidos seleccionados.
US7420030B2 (en)	2000-09-08	2008-09-02	The Board Of Regents Of The University Of Texas System	Aminopeptidase A (APA) targeting peptides for the treatment of cancer
AU2001288914A1 (en) *	2000-09-08	2002-03-22	Board Of Regents, The University Of Texas System	Biopanning and rapid analysis of selective interactive ligands (brasil)
US7452964B2 (en)	2001-09-07	2008-11-18	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en)	2000-09-08	2004-09-02	Wadih Arap	Human and mouse targeting peptides identified by phage display
US7671010B2 (en)	2002-08-30	2010-03-02	The Board Of Regents Of The University Of Texas System	Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US8507445B2 (en)	2001-09-07	2013-08-13	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7371719B2 (en)	2002-02-15	2008-05-13	Northwestern University	Self-assembly of peptide-amphiphile nanofibers under physiological conditions
EP1346729A1 (de) *	2002-03-19	2003-09-24	Cardiovascular Research Institute Maastricht	Zielgerichtete Therapie der myokardialen Angiogenese durch CD13/APN
US9321992B2 (en)	2002-06-14	2016-04-26	Case Western Reserve University	Cell targeting methods and compositions
CA2496938A1 (en) *	2002-08-30	2004-03-11	Board Of Regents, The University Of Texas System	Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US7554021B2 (en)	2002-11-12	2009-06-30	Northwestern University	Composition and method for self-assembly and mineralization of peptide amphiphiles
US20060263336A1 (en) *	2003-03-24	2006-11-23	Caplan Arnold I	Cell targeting methods and compositions
AU2004232314B2 (en) *	2003-04-22	2007-11-22	Ipsen Pharma S.A.S.	Peptide vectors
US20040248109A1 (en) *	2003-06-09	2004-12-09	Lawrence Greenfield	Methods for selecting protein binding moieties
WO2005026195A1 (en) *	2003-09-12	2005-03-24	Board Of Regents, The University Of Texas System	Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis
JP4870348B2 (ja) *	2003-12-04	2012-02-08	株式会社ペルセウスプロテオミクス	細胞表面抗原に対する抗体取得とその抗原同定
JP2011239784A (ja) *	2003-12-04	2011-12-01	Perseus Proteomics Inc	細胞表面抗原に対する抗体取得とその抗原同定
NZ547671A (en)	2003-12-05	2009-10-30	Univ Northwestern	Self-assembling peptide amphiphiles and related methods for growth factor delivery
US8377484B1 (en) *	2004-05-06	2013-02-19	Maria V. Tsiper	Tumor encapsulation for prevention and treatment of metastatic cancer disease
CN1294418C (zh) *	2004-08-09	2007-01-10	中国人民解放军南京军区南京总医院	检测白念珠菌菌丝蛋白抗体的方法及试剂盒
GB0422431D0 (en) *	2004-10-08	2004-11-10	Affitech As	Method
ITRM20040568A1 (it) *	2004-11-18	2005-02-18	Uni Degli Studi Di Roma Tor Vergata	Uso della tecnica "phage display" per l'identificazione di peptidi con capacita' di legame a cellule staminali/progenitore, peptidi cosi' ottenuti e loro usi.
WO2006114478A1 (en) *	2005-04-26	2006-11-02	Karyon-Ctt Ltd	Diagnostic and therapeutic agents
US8168181B2 (en)	2006-02-13	2012-05-01	Alethia Biotherapeutics, Inc.	Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
AU2007215334B2 (en)	2006-02-13	2013-11-21	Daiichi Sankyo Company, Limited	Polynucleotides and polypeptide sequences involved in the process of bone remodeling
WO2007104062A2 (en) *	2006-03-09	2007-09-13	The Board Of Regents Of The University Of Texas System	Compositions and methods based on peptide binding profiling
CA2679266A1 (en) *	2007-02-27	2008-09-04	Forerunner Pharma Research Co., Ltd.	Pharmaceutical composition comprising anti-grp78 antibody as active ingredient
US8076295B2 (en)	2007-04-17	2011-12-13	Nanotope, Inc.	Peptide amphiphiles having improved solubility and methods of using same
US7807630B2 (en) *	2007-09-14	2010-10-05	Vanderbilt University	Targeting of Notch3 receptor function for cancer therapy
CN102482347B (zh) *	2009-01-12	2017-04-26	希托马克斯医疗有限责任公司	修饰抗体组合物及其制备和使用方法
US8450271B2 (en)	2009-04-13	2013-05-28	Northwestern University	Peptide-based scaffolds for cartilage regeneration and methods for their use
WO2012109561A2 (en)	2011-02-11	2012-08-16	The Regents Of The University Of Michigan	Peptide compositions and methods for treating patients
EP2812349B1 (de) *	2012-02-10	2021-09-01	Cambridge Enterprise Limited	Verfahren zur charakterisierung von wechselwirkungsbereichen bei zielproteinen
WO2013149237A1 (en) *	2012-03-30	2013-10-03	Board Of Regents, The University Of Texas System	Targeting intracellular organelle zip codes with functional homing ligands from cell-internalizing phage combinatorial libraries
KR20150036274A (ko)	2012-07-19	2015-04-07	알레시아 바이오쎄라퓨틱스 인코포레이티드	항-siglec-15 항체
GB201308745D0 (en) *	2013-05-15	2013-06-26	Imp Innovations	Bacteriophage
CN103497236B (zh) *	2013-09-25	2017-05-10	浙江省医学科学院	靶向wisp‑1蛋白的特异性七肽及其应用
GB2522412A (en) *	2014-01-22	2015-07-29	Agency Science Tech & Res	Antimicrobial peptidomimetics
AU2015220920B2 (en)	2014-02-19	2019-09-12	F. Hoffmann-La Roche Ag	Blood brain barrier shuttle
ES2714921T3 (es) *	2014-05-19	2019-05-30	Valo Therapeutics Oy	Adenovirus oncolíticos recubiertos para vacunas contra el cáncer
CN105769909A (zh) *	2016-05-13	2016-07-20	云南舜喜再生医学工程有限公司	一种直接获得富含细胞因子血清的采血器及方法
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
KR101921836B1 (ko)	2017-11-23	2018-11-26	서울대학교병원	피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
WO2020068815A1 (en) *	2018-09-25	2020-04-02	Emory University	Nucleic acids for cell recognition and integration
CN109137086A (zh) *	2018-10-16	2019-01-04	梁耀极	一种改良的全长mRNA测序的建库方法
BR102019014302A2 (pt)	2019-07-10	2021-12-28	Universidade Federal de Uberlândia	Peptídeos recombinantes ligantes ao anticorpo tumoral específico para cancer de mama e uso
EP3767628B1 (de)	2019-07-18	2024-03-27	Bayer Aktiengesellschaft	Selektion von antikörpern / antikörperfragmenten
MX2022007465A (es) *	2019-12-17	2022-08-15	Univ Mie	Metodos y composiciones para evaluar y tratar fibrosis.
KR102749110B1 (ko) *	2021-11-04	2025-01-03	(주)케어젠	생리 활성을 갖는 펩타이드 및 그의 용도
GB202211043D0 (en) *	2022-07-28	2022-09-14	Univ Birmingham	Peptide agonist

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997010507A1 (en) *	1995-09-11	1997-03-20	La Jolla Cancer Research Foundation	Molecules that home to a selected organ or tissue in vivo and methods of identifying same
WO2000014215A1 (de) *	1998-09-07	2000-03-16	Eberhard-Karls-Universität Tübingen	Verfahren zur selektion von peptiden für zielgerichteten pharma- und markertransport und peptide damit entdeckt

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
US4957939A (en)	1981-07-24	1990-09-18	Schering Aktiengesellschaft	Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en)	1982-06-07	1984-09-18	Gansow Otto A	Metal chelate conjugated monoclonal antibodies
US5206347A (en)	1985-08-06	1993-04-27	La Jolla Cancer Research Foundation	Isolation and use of receptors binding to a peptide column
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5252296A (en)	1990-05-15	1993-10-12	Chiron Corporation	Method and apparatus for biopolymer synthesis
US5603872A (en)	1991-02-14	1997-02-18	Baxter International Inc.	Method of binding recognizing substances to liposomes
DK0525132T3 (da)	1991-02-14	1996-02-05	Baxter Int	Binding af genkendende stoffer til liposomer
US5329028A (en)	1992-08-05	1994-07-12	Genentech, Inc.	Carbohydrate-directed cross-linking reagents
CA2163620A1 (en) *	1993-05-28	1994-12-08	Michael V. Doyle	Method for selection of biologically active peptide sequences
US5492807A (en)	1993-11-19	1996-02-20	Santi; Daniel V.	Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US5622699A (en)	1995-09-11	1997-04-22	La Jolla Cancer Research Foundation	Method of identifying molecules that home to a selected organ in vivo
US6068829A (en)	1995-09-11	2000-05-30	The Burnham Institute	Method of identifying molecules that home to a selected organ in vivo
ES2313779T3 (es) *	1998-03-13	2009-03-01	The Burnham Institute	Moleculas que migran a diversos organos o tejidos seleccionados.

2001
- 2001-09-07 AT AT01968603T patent/ATE478141T1/de not_active IP Right Cessation
- 2001-09-07 EP EP01970681A patent/EP1315830A4/de not_active Withdrawn
- 2001-09-07 EP EP01968603A patent/EP1322755B1/de not_active Expired - Lifetime
- 2001-09-07 WO PCT/US2001/028124 patent/WO2002020822A2/en not_active Application Discontinuation
- 2001-09-07 JP JP2002525828A patent/JP2004530404A/ja not_active Withdrawn
- 2001-09-07 CA CA002421271A patent/CA2421271A1/en not_active Abandoned
- 2001-09-07 WO PCT/US2001/028045 patent/WO2002020724A2/en not_active Application Discontinuation
- 2001-09-07 WO PCT/US2001/027702 patent/WO2002020722A2/en not_active Application Discontinuation
- 2001-09-07 JP JP2002525730A patent/JP2004533803A/ja not_active Withdrawn
- 2001-09-07 CA CA002421200A patent/CA2421200A1/en not_active Abandoned
- 2001-09-07 DE DE60142840T patent/DE60142840D1/de not_active Expired - Lifetime
- 2001-09-07 EP EP01968683A patent/EP1315840A4/de not_active Withdrawn
- 2001-09-07 JP JP2002525731A patent/JP2004536020A/ja not_active Withdrawn
- 2001-09-07 JP JP2002525729A patent/JP2004515751A/ja not_active Withdrawn
- 2001-09-07 CA CA002421191A patent/CA2421191A1/en not_active Abandoned
- 2001-09-07 CA CA002421380A patent/CA2421380A1/en not_active Abandoned
- 2001-09-07 CA CA002421195A patent/CA2421195A1/en not_active Abandoned
- 2001-09-07 EP EP01970682A patent/EP1315512A4/de not_active Withdrawn
- 2001-09-07 EP EP01970671A patent/EP1315965A4/de not_active Withdrawn
- 2001-09-07 WO PCT/US2001/028044 patent/WO2002020723A2/en not_active Application Discontinuation
- 2001-09-07 EP EP08016646A patent/EP2028187A1/de not_active Withdrawn
- 2001-09-07 PT PT01968603T patent/PT1322755E/pt unknown
2010
- 2010-12-13 JP JP2010277247A patent/JP2011120587A/ja not_active Withdrawn
2011
- 2011-11-09 JP JP2011245272A patent/JP5591209B2/ja not_active Expired - Fee Related

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1997010507A1 (en) *	1995-09-11	1997-03-20	La Jolla Cancer Research Foundation	Molecules that home to a selected organ or tissue in vivo and methods of identifying same
WO2000014215A1 (de) *	1998-09-07	2000-03-16	Eberhard-Karls-Universität Tübingen	Verfahren zur selektion von peptiden für zielgerichteten pharma- und markertransport und peptide damit entdeckt

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
POLGREN A ET AL: "IDENTIFICATION OF MUSCLE HOMING SEQUENCES BY USING PHAGE DISPLAY LIBRARIES OF PEPTIDES", TUMOR BIOLOGY, KARGER, BASEL, CH, vol. 18, 1997, pages 77, XP002910201, ISSN: 1010-4283 *

Also Published As

Publication number	Publication date
EP1322755A4 (de)	2006-04-05
WO2002020722A3 (en)	2003-02-06
PT1322755E (pt)	2010-11-19
WO2002020822A2 (en)	2002-03-14
DE60142840D1 (de)	2010-09-30
EP1315512A4 (de)	2005-11-09
JP2011120587A (ja)	2011-06-23
WO2002020724A3 (en)	2002-07-11
EP2028187A1 (de)	2009-02-25
EP1315965A4 (de)	2006-04-05
CA2421195A1 (en)	2002-03-14
EP1315512A2 (de)	2003-06-04
EP1322755A1 (de)	2003-07-02
JP5591209B2 (ja)	2014-09-17
WO2002020724A2 (en)	2002-03-14
WO2002020723A2 (en)	2002-03-14
EP1322755B1 (de)	2010-08-18
WO2002020722A2 (en)	2002-03-14
JP2004536020A (ja)	2004-12-02
EP1315840A2 (de)	2003-06-04
JP2012065662A (ja)	2012-04-05
WO2002020723A3 (en)	2002-08-29
CA2421200A1 (en)	2002-03-14
EP1315965A2 (de)	2003-06-04
EP1315830A2 (de)	2003-06-04
JP2004533803A (ja)	2004-11-11
CA2421191A1 (en)	2002-03-14
CA2421380A1 (en)	2002-03-14
JP2004515751A (ja)	2004-05-27
WO2002020722A9 (en)	2003-08-21
EP1315840A4 (de)	2005-11-02
JP2004530404A (ja)	2004-10-07
CA2421271A1 (en)	2002-03-14
ATE478141T1 (de)	2010-09-15
WO2002020822A3 (en)	2002-06-27

Publication	Publication Date	Title
EP1315830A4 (de)	2005-10-19	Zusammensetzungen und verfahren zur zielgerichteten, in vivo einbringung von peptiden in den menschen
ES2629086T3 (es)	2017-08-07	Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
CY1107351T1 (el)	2012-12-19	Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
ES2167365T3 (es)	2002-05-16	Vectores adenovirales de origen animal y utilizacion en terapia genica.
ES2107041T3 (es)	1997-11-16	Variantes de activador de plasminogeno tisular obtenidos por glicosilacion, que presentan propiedades terapeuticas.
ATE286118T1 (de)	2005-01-15	Anwendungen für humane nicht autologe, mesenchymale stammzellen
ATE340560T1 (de)	2006-10-15	Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
WO1998049300A3 (en)	1999-03-11	Truncated vegf-related proteins
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE218879T1 (de)	2002-06-15	Therapeutische verwendungen von bakterizide/permeabilitätserhöhende protein dimer produkte
DE60018920D1 (de)	2005-04-28	Rekombinante adenovirale vektoren, die chimäre fiberproteine exprimieren, für die zellspezifische infektion und genomische integration
ATE228016T1 (de)	2002-12-15	Lebendvakzine zur behandlung von tumorerkrankungen
WO1998039426A3 (en)	1998-10-29	Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products
DK1677833T3 (da)	2010-05-17	Virusvektor til anvendelse til in vivo-genterapi af Parkinsons sygdom
ATE287958T1 (de)	2005-02-15	Verbesserte krebstherapie
ATE423574T1 (de)	2009-03-15	Dominant-negativer plb mutant zur behandlung der herzerkrankungen
ATE320270T1 (de)	2006-04-15	Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
NZ504445A (en)	2002-08-28	Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
DE60129069D1 (de)	2007-08-09	Hepatitis B Virus Vektoren für Gentherapie
AU6987696A (en)	1997-03-27	The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells
ATE239749T1 (de)	2003-05-15	Phosphor-enthaltende dendrimere als transfektionsagente
KR100488038B1 (ko)	2005-05-09	기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
ATE371737T1 (de)	2007-09-15	Proteaseresistente flint-analoge
ATE210990T1 (de)	2002-01-15	Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
MX9708615A (es)	1998-06-28	Terapia de genes animales.

Legal Events

Date	Code	Title	Description
2003-04-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-06-04	17P	Request for examination filed	Effective date: 20030306
2003-06-04	AK	Designated contracting states	Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-06-04	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2005-06-01	RIC1	Information provided on ipc code assigned before grant	Ipc: 7G 01N 33/50 B Ipc: 7C 12N 15/10 B Ipc: 7A 61K 49/14 B Ipc: 7A 61K 49/00 B Ipc: 7C 12N 15/09 B Ipc: 7C 12N 15/07 B Ipc: 7C 12N 7/02 B Ipc: 7C 12N 5/08 B Ipc: 7C 12N 5/00 B Ipc: 7C 12P 21/00 B Ipc: 7C 12Q 1/70 B Ipc: 7C 12Q 1/24 B Ipc: 7C 12Q 1/02 A
2005-10-19	A4	Supplementary search report drawn up and despatched	Effective date: 20050901
2006-04-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2006-05-31	18D	Application deemed to be withdrawn	Effective date: 20051115